Skip to main content
  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
Logo image Logo image
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline (Opens in a new tab/window)
      • PBM Guidelines (Opens in a new tab/window)
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines (Opens in a new tab/window)
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Search

  • Donate Blood (Opens in a new tab/window)
  • About NBA
  • News and updates
  • Resources
  • BloodPortal login (Opens in a new tab/window)
  • Blood Products
    • Blood Products
    • National Product Price List
    • Fresh Blood Products
    • Albumin Products
    • Clotting Factor and Other Products
    • Immunoglobulin Products
      • Immunoglobulin Usage and Data
      • Intravenous Immunoglobulin (IVIg)
      • Subcutaneous Immunoglobulin (SCIg)
      • Normal Human Immunoglobulin (NHIg)
      • Hyperimmune Immunoglobulin Products
    • Access and Ordering
      • BloodSTAR for Ig Products
      • BloodSTAR Registration Form
      • BloodNet for Blood Products from Lifeblood
      • BloodNet System Interface
      • Frequently Asked Questions
    • Blood Product Management
      • Inventory Management
      • Blood Product Wastage
      • Blood and Inventory Management Resources
      • Case Studies
      • Single Unit Transfusion Guide
  • Supply System
    • Supply System
    • Managing Blood Supply
      • Risk Management
      • National Stewardship Program
      • Blood Product Labelling
    • Governance for Immunoglobulin Products
      • National Immunoglobulin Governance Committees
      • Criteria for Immunoglobulin Products
    • Suppliers and Commercial Supply Contracts
      • Fresh Blood Product Supply and Lifeblood
      • Plasma and Recombinant Product Supply
      • Imported Product Supply
      • Red Cell Diagnostic Product Supply
    • Australian Health Provider Access to Blood and Blood Products
    • Overseas Supply of Blood Products
  • Clinical Guidance
    • Clinical Guidance
      • Rh D Ig Guideline
      • PBM Guidelines
    • National Standards
    • Immunoglobulin
    • Patient Blood Management
      • Patient Blood Management (PBM) Resources
    • Transfusion-related Adverse Events
    • Bleeding Disorders
      • Australian Bleeding Disorders Registry (ABDR)
    • eLearning Courses
    • Public Consultations
    • Patient Blood Management Guidelines
  • Data and Research
    • Data and Research
    • Data and Reporting
    • Research Funding Program
      • Successful Grant Rounds
  • Patient Information
    • Patient information
    • Bleeding disorders
    • Blood disorders
    • Travelling with blood products
    • MyABDR app and the ABDR

Vulnerability Disclosure Program

  • Home
  • Vulnerability Disclosure Program

The security of our systems is very important to us. While we make every effort to keep our systems secure, vulnerabilities may still exist.

Working with the security community is something we embrace. We have implemented our Vulnerability Disclosure Program to let you responsibly share your findings with us.

The purpose of this program is to receive, assess and remediate cyber vulnerabilities. We encourage good-willed security researchers and professionals to report our vulnerabilities to us. This program is not intended for general Agency services enquiries. We will not respond to any contact through this process that is unrelated to a potential security vulnerability.

If you discover a potential vulnerability in any of our systems, services or products, notify us as soon as possible. To notify us, follow the process outlined below. 

Program Scope

Our Vulnerability Disclosure Program covers any:

  • Product or service owned by us to which you have legal access, and
  • Product, service and infrastructure we provide to shared service partners to which you have legal access.

 

Disallowed Activities

To ensure the integrity of the program, there are several research activities that are disallowed under this Program. We encourage security researchers and professionals to familiarise themselves with the following list before commencing any research.

The following types of research are disallowed:

  • Social engineering or phishing
  • Denial of Service (DoS) or Distributed DoS (DDoS) attacks
  • Physical attacks
  • Attempts to modify or destroy data
  • Clickjacking
  • Accessing or attempting to access accounts or data that does not belong to you
  • Any activity that violates any law
  • Posting, transmitting, uploading, linking to, or sending any malware
  • Automated vulnerability scan reports
  • Leverage deceptive techniques
  • Exfiltrating any data under any circumstances
  • Testing third-party websites, applications, or services that integrate with services or products
  • Disclosure of known public files or directories
  • Lack of Secure or HTTP Only flags on non-sensitive cookies
  • Usage of a known vulnerable library or framework without valid attack scenario

Do not report security vulnerabilities relating to missing security controls or protections that are not directly exploitable. Examples include:

  • Weak, insecure or misconfigured SSL (secure sockets layer) or TLS (transport layer security) certificates
  • Misconfigured DNS (domain name system) records including, but not limited to SPF (sender policy framework) and DMARC (domain-based message authentication reporting and conformance)
  • Missing security HTTP (hypertext transfer protocol) headers (for example, permissions policy), and
  • Theoretical cross-site request forgery and cross-site framing attacks​

 

How to disclose a vulnerability

To report a potential security vulnerability email security@blood.gov.au

Make sure you include as much information as possible:

  • Details of the potential security vulnerability
  • List of potentially affected products and services (where possible)
  • Steps to reproduce the vulnerability
  • Proof-of-concept code (where applicable)
  • Names of any test accounts you have created (where applicable)
  • Your contact details (if you choose), and
  • Whether you would like public acknowledgement for your contribution (under the acknowledgments section of this webpage), and the name you would like to be acknowledged under.

 

Post-Disclosure Process

When you report a vulnerability, we will:

  • Respond to you within 2 business days, and
  • Recognise your contribution to our program by publishing your name or alias on our public website if you indicate you would like public acknowledgement.

We will not:

  • Financially compensate you for reporting, or
  • Share your details with any other organisation, without your permission.

 

Acknowledgements 

The National Blood Authority recognises the following individuals for providing their time and expertise to make the NBA a more secure entity:

  • Omkar Mahadev Gore, February 2025

Last updated: 03 Dec 2024

Back to top

The National Blood Authority acknowledges the Traditional Owners and Custodians of Country throughout Australia, and their continuing connection to land, water and community. We pay our respects to the people, the cultures and the elders past, present and emerging.

National Blood Authority

  • About the NBA
  • Work with us
  • Contact Us
  • Data and reporting
  • Freedom of information
  • Public interest disclosure
  • Resources
  • Accessibility
  • Privacy
  • Copyright
  • Disclaimer
  • BloodPortal Terms and Conditions of Use

Information

  • Blood Products
  • Managing blood supply
  • Supply systems
  • Clinical guidance
  • Patient information
  • Data and research
  • Website feedback